A detailed history of Bank Of America Corp transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 177,666 shares of DAWN stock, worth $2.74 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
177,666
Previous 127,589 39.25%
Holding current value
$2.74 Million
Previous $2.11 Million 16.18%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$12.03 - $17.69 $602,426 - $885,862
50,077 Added 39.25%
177,666 $2.45 Million
Q1 2024

May 15, 2024

SELL
$13.56 - $17.46 $437,920 - $563,870
-32,295 Reduced 20.2%
127,589 $2.11 Million
Q4 2023

Feb 14, 2024

SELL
$9.68 - $15.37 $518,731 - $823,647
-53,588 Reduced 25.1%
159,884 $2.33 Million
Q2 2023

Aug 14, 2023

SELL
$11.74 - $14.47 $236,185 - $291,107
-20,118 Reduced 8.61%
213,472 $2.55 Million
Q1 2023

May 12, 2023

BUY
$12.75 - $23.41 $1.39 Million - $2.55 Million
109,117 Added 87.66%
233,590 $3.12 Million
Q4 2022

Feb 10, 2023

SELL
$18.77 - $22.0 $595,609 - $698,104
-31,732 Reduced 20.31%
124,473 $2.68 Million
Q3 2022

Nov 14, 2022

BUY
$16.44 - $26.57 $2.08 Million - $3.36 Million
126,498 Added 425.82%
156,205 $3.13 Million
Q2 2022

Aug 12, 2022

BUY
$5.72 - $17.9 $136,462 - $427,040
23,857 Added 407.81%
29,707 $531,000
Q1 2022

May 16, 2022

BUY
$9.12 - $17.47 $1,504 - $2,882
165 Added 2.9%
5,850 $58,000
Q4 2021

Feb 08, 2022

BUY
$15.65 - $26.33 $81,395 - $136,942
5,201 Added 1074.59%
5,685 $96,000
Q3 2021

Nov 15, 2021

SELL
$20.0 - $27.92 $4,320 - $6,030
-216 Reduced 30.86%
484 $11,000
Q2 2021

Sep 13, 2021

BUY
$19.0 - $23.69 $13,300 - $16,583
700 New
700 $16,000

Others Institutions Holding DAWN

About Day One Biopharmaceuticals, Inc.


  • Ticker DAWN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,461,104
  • Market Cap $1.13B
  • Description
  • Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...
More about DAWN
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.